학술논문
Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials
Document Type
Article
Author
Source
In Clinical Therapeutics April 2016 38(4):843-862
Subject
Language
ISSN
0149-2918